Filing Details
- Accession Number:
- 0001062993-21-000291
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-12 16:11:51
- Reporting Period:
- 2021-01-08
- Accepted Time:
- 2021-01-12 16:11:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1616212 | Trillium Therapeutics Inc. | TRIL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1838047 | Robert Uger | C/O Trillium Therapeutics Inc. 2488 Dunwin Drive Mississauga A6 L5L 1J9 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2021-01-08 | 5,600 | $11.01 | 5,600 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2021-01-08 | 5,600 | $15.82 | 0 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2021-01-08 | 2,917 | $3.33 | 2,917 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2021-01-08 | 2,917 | $15.51 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2021-01-08 | 5,600 | $0.00 | 5,600 | $11.01 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2021-01-08 | 2,917 | $0.00 | 2,917 | $3.33 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 23,473 | 2026-05-27 | No | 4 | M | Direct | |
| 64,167 | 2028-11-08 | No | 4 | M | Direct |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.78 to $15.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.39 to $15.635 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.
Billionaire Hedge Funds
